Long-term Visual Outcome and Prognostic Factors After Intravitreal Ranibizumab Injections for Polypoidal Choroidal Vasculopathy – Corrected Proof

Purpose: To evaluate long-term visual outcome and investigate the prognostic factors after anti–vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV).Design: Retrospective study.Methods: Analyses were done among 36 eyes (36 patients) with naïve PCV that were treated with intravitreal ranibizumab injections and completed at least 3-year follow-up. All clinical data, including baseline characteristics; imaging data from fluorescein angiography, indocyanine green angiography, and optical coherence tomography; presence of recurrence; and best-corrected visual acuity (BCVA) were investigated.Results: During mean follow-up of 42.58 ± 12.59 months, mean numbers of anti-VEGF injection were 11.45 ± 7.81. Twenty-four eyes (66.7%) showed at least 1 (Read more...)

Full Story →